Soligenix Future Growth
Future criteria checks 0/6
Soligenix's earnings are forecast to decline at 17.3% per annum while its annual revenue is expected to grow at 3.3% per year. EPS is expected to grow by 0.8% per annum.
Key information
-17.3%
Earnings growth rate
0.8%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 3.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 20 Mar 2024 |
Recent future growth updates
Recent updates
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell Lymphoma
Oct 05U.S. FDA awards $2.6M grant for expanded study of Soligenix's HyBryte for skin cancer
Sep 12Soligenix announces $2.6M FDA grant to further study blood cancer candidate
Sep 06Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Sep 06Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M
Aug 12Soligenix, SERB Pharma team up to develop therapy for ricin poisoning
Jul 25Is Soligenix (NASDAQ:SNGX) Using Debt Sensibly?
Apr 22Is Soligenix (NASDAQ:SNGX) Using Too Much Debt?
Jan 03Shareholders May Find It Hard To Justify Increasing Soligenix, Inc.'s (NASDAQ:SNGX) CEO Compensation For Now
Sep 17Health Check: How Prudently Does Soligenix (NASDAQ:SNGX) Use Debt?
Aug 30Is Soligenix (NASDAQ:SNGX) Weighed On By Its Debt Load?
May 08What Type Of Returns Would Soligenix's(NASDAQ:SNGX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Mar 16Soligenix inks supply and distribution deal for SGX301 companion light device in cancer
Jan 07Soligenix receives $1.5M grant advancing COVID-19 vaccine development
Dec 28Soligenix's SGX942 flunks oral mucositis study in cancer patients, shares plummet 44%
Dec 22Soligenix announces $20M strategic convertible debt financing agreement
Dec 16Why Soligenix's (NASDAQ:SNGX) CEO Pay Matters
Nov 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1 | -11 | N/A | N/A | 2 |
12/31/2025 | 1 | -10 | N/A | N/A | 2 |
12/31/2024 | 1 | -9 | N/A | N/A | 2 |
12/31/2023 | 1 | -6 | -9 | -9 | N/A |
9/30/2023 | 1 | -8 | -10 | -10 | N/A |
6/30/2023 | 1 | -10 | -11 | -11 | N/A |
3/31/2023 | 1 | -10 | -12 | -12 | N/A |
12/31/2022 | 1 | -14 | -13 | -13 | N/A |
9/30/2022 | 1 | -15 | -12 | -12 | N/A |
6/30/2022 | 1 | -15 | -12 | -12 | N/A |
3/31/2022 | 1 | -15 | -11 | -11 | N/A |
12/31/2021 | 1 | -13 | -12 | -12 | N/A |
9/30/2021 | 1 | -13 | -13 | -13 | N/A |
6/30/2021 | 1 | -12 | -13 | -13 | N/A |
3/31/2021 | 2 | -12 | -13 | -13 | N/A |
12/31/2020 | 2 | -18 | -11 | -11 | N/A |
9/30/2020 | 3 | -15 | -10 | -10 | N/A |
6/30/2020 | 3 | -16 | -9 | -9 | N/A |
3/31/2020 | 4 | -15 | -8 | -8 | N/A |
12/31/2019 | 5 | -9 | -8 | -8 | N/A |
9/30/2019 | 5 | -10 | -8 | -8 | N/A |
6/30/2019 | 5 | -9 | -6 | -6 | N/A |
3/31/2019 | 5 | -8 | -8 | -8 | N/A |
12/31/2018 | 5 | -9 | -7 | -7 | N/A |
9/30/2018 | 6 | -8 | -7 | -7 | N/A |
6/30/2018 | 6 | -7 | -7 | -7 | N/A |
3/31/2018 | 5 | -8 | -6 | -6 | N/A |
12/31/2017 | 5 | -7 | -7 | -7 | N/A |
9/30/2017 | 6 | -5 | N/A | -6 | N/A |
6/30/2017 | 7 | -6 | N/A | -6 | N/A |
3/31/2017 | 9 | -4 | N/A | -6 | N/A |
12/31/2016 | 10 | -3 | N/A | -5 | N/A |
9/30/2016 | 12 | -5 | N/A | -5 | N/A |
6/30/2016 | 13 | -1 | N/A | -4 | N/A |
3/31/2016 | 11 | -4 | N/A | -5 | N/A |
12/31/2015 | 9 | -8 | N/A | -5 | N/A |
9/30/2015 | 8 | -4 | N/A | -4 | N/A |
6/30/2015 | 7 | -11 | N/A | -5 | N/A |
3/31/2015 | 7 | -8 | N/A | -4 | N/A |
12/31/2014 | 7 | -7 | N/A | -2 | N/A |
9/30/2014 | 6 | -8 | N/A | -3 | N/A |
6/30/2014 | 4 | -10 | N/A | -4 | N/A |
3/31/2014 | 3 | -12 | N/A | -4 | N/A |
12/31/2013 | 3 | -10 | N/A | -4 | N/A |
9/30/2013 | 3 | -12 | N/A | -4 | N/A |
6/30/2013 | 3 | -6 | N/A | -3 | N/A |
3/31/2013 | 3 | -4 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SNGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SNGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SNGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SNGX's revenue (3.3% per year) is forecast to grow slower than the US market (8.2% per year).
High Growth Revenue: SNGX's revenue (3.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SNGX's Return on Equity is forecast to be high in 3 years time